Ahmad Ibrahim Ahmad Zainuddin: Aspirin in Primary Prevention Is Now a Carefully Selected Exception
Ahmad Ibrahim Ahmad Zainuddin, Medical Advisor and Occupational Health Doctor at eBen Assist Sdn Bhd, shared on LinkedIn:
“A client asked me recently, ‘If someone is high risk for cardiovascular disease, should we start aspirin for primary prevention?’
For years, aspirin symbolized proactive medicine. One small tablet to prevent the first myocardial infarction or stroke. It felt logical, accessible, and safe.
But modern evidence tells a more nuanced story.
The ASCEND trial showed that in patients with diabetes, aspirin reduced serious vascular events (8.5% vs 9.6%) but increased major bleeding (4.1% vs 3.2%) (ASCEND Study Collaborative Group, NEJM, 2018).
The ASPREE trial found no cardiovascular mortality benefit in healthy older adults, yet bleeding risk rose significantly (McNeil et al., NEJM, 2018).
A meta-analysis of over 160,000 patients captured the dilemma clearly. The absolute reduction in cardiovascular events was about 0.4%, while major bleeding increased by roughly 0.5% (Zheng et al., JAMA, 2019).
Nearly symmetrical benefit and harm.
Why did aspirin lose its preventive dominance?
Because cardiovascular prevention improved. Blood pressure is treated earlier, statins are widely used, diabetes care is more cardioprotective, and smoking rates have declined. When baseline risk falls, aspirin’s absolute benefit shrinks, but bleeding risk does not.
This is why the USPSTF 2022 no longer recommends routine aspirin initiation for primary prevention, particularly in adults aged 60 and above, and instead supports individualized decisions for selected adults aged 40–59.
Primary prevention today is no longer pill-centric. It is risk-centric.
Tight hypertension control, appropriate statin therapy, diabetes optimization, smoking cessation, metabolic health, and early detection of atrial fibrillation prevent far more first events than blanket aspirin ever did.
Aspirin remains powerful in secondary prevention. In primary prevention, however, it has shifted from default therapy to a carefully selected exception.
Perhaps this reflects the quiet maturity of modern medicine. Good prevention is not about doing more, but about doing what matters most for the right patient at the right time.
Curious to hear from colleagues. Has aspirin prescribing for primary prevention declined in your practice?”
Stay updated with Hemostasis Today.
-
Mar 20, 2026, 17:47Julie Rayes: Commenting on a Seminal NEJM Study Solving the Mystery of VITT
-
Mar 20, 2026, 17:45William Tembo: Advancing Stroke Care by Validating Acute Ischemic Treatment
-
Mar 20, 2026, 17:37Renjith Vijayakumar Selvarani: New Nanoparticle Approach Clears Brain Plaque and Restores Memory
-
Mar 20, 2026, 17:35Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
-
Mar 20, 2026, 17:17Angelo Cascio Rizzo: CTA-Based Plaque RADS Improves Risk Stratification in ESUS
-
Mar 20, 2026, 17:09Clinical Practice Guidelines for Platelet Transfusion in Non-Surgical and Non-Traumatic Settings – CEBaP
-
Mar 20, 2026, 17:07The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
-
Mar 20, 2026, 17:05Pierre Fontana: Launching the European Interuniversity Certificate in Clinical Haemostasis
-
Mar 20, 2026, 16:49Wolfgang Miesbach: A Pivotal Step Forward for Patients with von Willebrand Disease Across All Subtypes